Skip Navigation
Skip to contents

JMD : Journal of Movement Disorders

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
24 "Deep brain stimulation"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Letter to the editor
Deep Brain Stimulation in Advanced Parkinson’s Disease: An Uncommon Case of Allergic Encephalitis
Jyun-Yi Chen, Yen-Chung Chen, Shey-Lin Wu
Received November 16, 2023  Accepted April 12, 2024  Published online April 15, 2024  
DOI: https://doi.org/10.14802/jmd.23237    [Accepted]
  • 280 View
  • 8 Download
PDF
Review Article
Pallidus Stimulation for Chorea-Acanthocytosis: A Systematic Review and Meta-Analysis of Individual Data
Weibin He, Chenhui Li, Hongjuan Dong, Lingmin Shao, Bo Yin, Dianyou Li, Liguo Ye, Ping Hu, Chencheng Zhang, Wei Yi
J Mov Disord. 2022;15(3):197-205.   Published online July 26, 2022
DOI: https://doi.org/10.14802/jmd.22003
  • 3,564 View
  • 307 Download
  • 2 Web of Science
AbstractAbstract PDFSupplementary Material
A significant proportion of patients with chorea-acanthocytosis (ChAc) fail to respond to standard therapies. Recent evidence suggests that globus pallidus internus (GPi) deep brain stimulation (DBS) is a promising treatment option; however, reports are few and limited by sample sizes. We conducted a systematic literature review to evaluate the clinical outcome of GPi-DBS for ChAc. PubMed, Embase, and Cochrane Library databases were searched for relevant articles published before August 2021. The improvement of multiple motor and nonmotor symptoms was qualitatively presented. Improvements in the Unified Huntington’s Disease Rating Scale motor score (UHDRS-MS) were also analyzed during different follow-up periods. A multivariate linear regression analysis was conducted to identify potential predictors of clinical outcomes. Twenty articles, including 27 patients, were eligible. Ninety-six percent of patients with oromandibular dystonia reported significant improvement. GPi-DBS significantly improved the UHDRS-motor score at < 6 months (p < 0.001) and ≥ 6 months (p < 0.001). The UHDRS-motor score improvement rate was over 25% in 75% (15/20 cases) of patients at long-term follow-up (≥ 6 months). The multiple linear regression analysis showed that sex, age at onset, course of disease, and preoperative movement score had no linear relationship with motor improvement at long-term follow-up (p > 0.05). GPi-DBS is an effective and safe treatment in most patients with ChAc, but no reliable predictor of efficacy has been found. Oromandibular dystonia-dominant patients might be the best candidates for GPi-DBS.
Original Articles
Long-Term Outcomes of Deep Brain Stimulation in Pantothenate Kinase-Associated Neurodegeneration-Related Dystonia
Kyung Ah Woo, Han-Joon Kim, Seung-Ho Jeon, Hye Ran Park, Kye Won Park, Seung Hyun Lee, Sun Ju Chung, Jong-Hee Chae, Sun Ha Paek, Beomseok Jeon
J Mov Disord. 2022;15(3):241-248.   Published online July 26, 2022
DOI: https://doi.org/10.14802/jmd.22002
  • 2,859 View
  • 172 Download
  • 2 Web of Science
  • 2 Crossref
AbstractAbstract PDFSupplementary Material
Objective
To investigate the long-term clinical outcomes of pallidal deep brain stimulation (GPi-DBS) in patients with pantothenate kinase-associated neurodegeneration (PKAN).
Methods
We reviewed the records of patients with genetically confirmed PKAN who received bilateral GPi-DBS for refractory dystonia and were clinically followed up for at least 2 years postoperatively at two centers in Korea. Pre- and postoperative Burke– Fahn–Marsden Dystonia Rating Scale motor subscale (BFMDRS-M) scores, disability subscale (BFMDRS-D) scores, and qualitative clinical information were prospectively collected. Descriptive analysis was performed for BFMDRS-M scores, BFMDRSD scores, and the orofacial, axial, and limb subscores of the BFMDRS-M at 6–12, 24–36, and 60–72 months postoperatively.
Results
Five classic-type, four atypical-type, and one unknown-type PKAN cases were identified. The mean preoperative BFMDRS-M score was 92.1 for the classic type and 38.5 for the atypical or unknown type, with a mean BFMDRS follow-up of 50.7 months and a clinical follow-up of 69.0 months. The mean improvements in BFMDRS-M score were 11.3%, 41.3%, and 30.5% at 6–12, 24–36, and 60–72 months, respectively. In four patients with full regular evaluations until 60–72 months, improvements in the orofacial, axial, and limb subscores persisted, but the disability scores worsened from 24–36 months post-operation compared to the baseline, mainly owing to the aggravation of eating and feeding disabilities.
Conclusion
The benefits of GPi-DBS on dystonia may persist for more than 5 years in PKAN. The effects on patients’ subjective disability may have a shorter duration despite improvements in dystonia owing to the complex manifestations of PKAN.

Citations

Citations to this article as recorded by  
  • Deep Brain Stimulation for Refractory Status Dystonicus in Children: Multicenter Case Series and Systematic Review
    Lindsey M. Vogt, Han Yan, Brendan Santyr, Sara Breitbart, Melanie Anderson, Jürgen Germann, Karlo J. Lizarraga, Angela L. Hewitt, Alfonso Fasano, George M. Ibrahim, Carolina Gorodetsky
    Annals of Neurology.2024; 95(1): 156.     CrossRef
  • Surgical treatment of movement disorders in neurometabolic conditions
    Alonso Zea Vera, Andrea L. Gropman
    Frontiers in Neurology.2023;[Epub]     CrossRef
Development of Clinical Milestones in Parkinson’s Disease After Bilateral Subthalamic Deep Brain Stimulation
Jed Noel A. Ong, Jung Hwan Shin, Seungho Jeon, Chan Young Lee, Han-Joon Kim, Sun Ha Paek, Beomseok Jeon
J Mov Disord. 2022;15(2):124-131.   Published online May 26, 2022
DOI: https://doi.org/10.14802/jmd.21106
  • 2,440 View
  • 137 Download
  • 1 Web of Science
  • 1 Crossref
AbstractAbstract PDFSupplementary Material
Objective
Deep brain stimulation of the subthalamic nucleus (STN-DBS) in Parkinson’s disease (PD) patients does not halt disease progression, as these patients will progress and develop disabling non-levodopa responsive symptoms. These features may act as milestones that represent the overall functionality of patients after DBS. The objective of this study was to investigate the development of clinical milestones in advanced PD patients who underwent bilateral STN-DBS.
Methods
The study evaluated PD patients who underwent STN-DBS at baseline up to their last follow-up using the Unified Parkinson’s Disease Rating Scale and Hoehn and Yahr scale. The symptoms of hallucinations, dysarthria, dysphagia, frequent falls, difficulty walking, cognitive impairment and the loss of autonomy were chosen as the clinical milestones.
Results
A total of 106 patients with a mean age of 47.21 ± 10.52 years at disease onset, a mean age of 58.72 ± 8.74 years at surgery and a mean disease duration of 11.51 ± 4.4 years before surgery were included. Initial improvement of motor symptoms was seen after the surgery with the appearance of clinical milestones over time. Using the moderately disabling criteria, 81 patients (76.41%) developed at least one clinical milestone, while 48 patients (45.28%) developed a milestone when using the severely disabling criteria.
Conclusion
STN-DBS has a limited effect on axial and nonmotor symptoms of the PD patients, in contrast to the effect on motor symptoms. These symptoms may serve as clinical milestones that can convey the status of PD patients and its impact on the patients and their caregivers. Therefore, advanced PD patients, even those treated with bilateral STN-DBS, will still require assistance and cannot live independently in the long run.

Citations

Citations to this article as recorded by  
  • Unveiling the Impact of Outpatient Physiotherapy on Specific Motor Symptoms in Parkinson’s Disease: A Prospective Cohort Study
    Yuta Terasawa, Koki Ikuno, Shintaro Fujii, Yuki Nishi, Emi Tanizawa, Sachio Nabeshima, Yohei Okada
    Brain & Neurorehabilitation.2023;[Epub]     CrossRef
Case Report
Deep Brain Stimulation for Cockayne Syndrome-Associated Movement Disorder
Joseph S. Domino, Rose Gelineau-Morel, Christian Kaufman
J Mov Disord. 2022;15(1):62-65.   Published online November 3, 2021
DOI: https://doi.org/10.14802/jmd.21005
  • 3,273 View
  • 245 Download
  • 1 Web of Science
  • 1 Crossref
AbstractAbstract PDFSupplementary Material
Cockayne syndrome (CS) is a rare progeroid disorder characterized by multisystem degeneration, including neurological dysfunction, for which deep brain stimulation (DBS) is a proposed treatment. This study represents only the third case of DBS for CS-associated movement disorder and the first in which both proposed targets had devices implanted, allowing for direct comparison. A case of DBS for CS-associated movement disorder is presented. Previous literature documents two cases with one targeting the ventral intermediate nucleus of the thalamus (VIM) and the other targeting the globus pallidus interna (GPi). Our patient underwent stimulation of GPi nuclei followed by repositioning to VIM nuclei with improved symptom control using VIM stimulation. In all cases, there was a significant clinical benefit without off-target effects. CS-associated movement disorder exhibits phenotypic variability for which DBS is a viable treatment. Target selection should be driven by clinical phenotype.

Citations

Citations to this article as recorded by  
  • Cockayne syndrome type 3 with dystonia‐ataxia and clicking blinks
    Özge Berna Gültekin‐Zaim, Gül Yalçın‐Çakmaklı, Ayşe İlksen Çolpak, Pelin Özlem Şimşek‐Kiper, Gülen Eda Utine, Bülent Elibol
    Movement Disorders Clinical Practice.2023;[Epub]     CrossRef
Original Article
The Queensland Parkinson’s Project: An Overview of 20 Years of Mortality from Parkinson’s Disease
Peter Cornelis Poortvliet, Alexander Gluch, Peter A. Silburn, George D. Mellick
J Mov Disord. 2021;14(1):34-41.   Published online December 7, 2020
DOI: https://doi.org/10.14802/jmd.20034
  • 9,640 View
  • 214 Download
  • 11 Web of Science
  • 11 Crossref
AbstractAbstract PDF
Objective
The consensus is that life expectancy for individuals with Parkinson’s disease (PD) is reduced, but estimations vary. We aimed to provide an overview of 20 years of mortality and risk factor data from the Queensland Parkinson’s Project.
Methods
The analysis included 1,334 PD and 1,127 control participants. Preliminary analysis of baseline characteristics (sex, age at onset, family history, smoking status, pesticide exposure, depression and neurosurgery) was conducted, and Kaplan–Meier curves were generated for each potential risk factor. Standardized mortality ratios (SMRs) were calculated comparing this cohort to the general Australian population. Cox proportional hazards regression modeling was used to analyze potential predictors of mortality.
Results
In total, 625 (46.8%) PD and 237 (21.0%) control participants were deceased. Mean disease duration until death was 15.3 ± 7.84 years. Average ages at death were 78.0 ± 7.4 years and 80.4 ± 8.4 years for the deceased PD and control participants, respectively. Mortality was significantly increased for PD in general {SMR = 2.75 [95% confidence interval (CI): 2.53–2.96]; p = 0.001}. SMRs were slightly higher for women and those with an age of onset before 60 years. Multivariate analysis showed that deep brain stimulation (DBS) treatment was associated with lower mortality [hazard ratio (HR) = 0.76; 95% CI: 0.59–0.98], while occasional pesticide exposure increased mortality risk (HR = 1.48; 95% CI: 1.17–1.88). Family history of PD, smoking and depression were not independent predictors of mortality.
Conclusion
Mortality in PD is increased. Sex, age at onset and occasional pesticide exposure were independent determinants of increased mortality, while DBS treatment was associated with reduced mortality.

Citations

Citations to this article as recorded by  
  • Update: Descriptive epidemiology of Parkinson disease
    Nikolas Grotewold, Roger L. Albin
    Parkinsonism & Related Disorders.2024; 120: 106000.     CrossRef
  • Indication for molecular testing by multiplex ligation‐dependent probe amplification in parkinsonism
    E. Mutez, M. Swiderski, D. Devos, C. Moreau, G. Baille, A. Degardin, G. Ryckewaert, N. Carriere, A. Kreisler, C. Simonin, N. Rouaix, M. Tir, P. Krystkowiak, N. Ramdane, M. Génin, B. Sablonnière, L. Defebvre, V. Huin
    European Journal of Neurology.2023; 30(6): 1667.     CrossRef
  • Different pieces of the same puzzle: a multifaceted perspective on the complex biological basis of Parkinson’s disease
    Amica C. Müller-Nedebock, Marieke C. J. Dekker, Matthew J. Farrer, Nobutaka Hattori, Shen-Yang Lim, George D. Mellick, Irena Rektorová, Mohamed Salama, Artur F. S. Schuh, A. Jon Stoessl, Carolyn M. Sue, Ai Huey Tan, Rene L. Vidal, Christine Klein, Soraya
    npj Parkinson's Disease.2023;[Epub]     CrossRef
  • Effects of omega-3 polyunsaturated fatty acids on the levels of pro- and anti-inflammatory cytokines and lipid profile in patients with Parkinson's disease
    Sara Mohammadi, Mirmohsen Sharifi Bonab, Mahdyieh Hamed Behzad, Bahram Pourghassem Gargari
    Nutrition Clinique et Métabolisme.2023; 37(3): 181.     CrossRef
  • The elephant in the room: critical reflections on mortality rates among individuals with Parkinson’s disease
    Lisanne J. Dommershuijsen, Sirwan K. L. Darweesh, Yoav Ben-Shlomo, Benzi M. Kluger, Bastiaan R. Bloem
    npj Parkinson's Disease.2023;[Epub]     CrossRef
  • Mortality of Parkinson’s disease in Italy from 1980 to 2015
    Monica Ulivelli, Daiana Bezzini, Lucia Kundisova, Ilaria Grazi, Mario Alberto Battaglia, Nicola Nante, Simone Rossi
    Neurological Sciences.2022; 43(6): 3603.     CrossRef
  • A nationwide study of the incidence, prevalence and mortality of Parkinson’s disease in the Norwegian population
    Brage Brakedal, Lilah Toker, Kristoffer Haugarvoll, Charalampos Tzoulis
    npj Parkinson's Disease.2022;[Epub]     CrossRef
  • Australian Parkinson’s Genetics Study (APGS): pilot (n=1532)
    Svetlana Bivol, George D Mellick, Jacob Gratten, Richard Parker, Aoibhe Mulcahy, Philip E Mosley, Peter C Poortvliet, Adrian I Campos, Brittany L Mitchell, Luis M Garcia-Marin, Simone Cross, Mary Ferguson, Penelope A Lind, Danuta Z Loesch, Peter M Vissche
    BMJ Open.2022; 12(2): e052032.     CrossRef
  • Therapeutic targeting of mitophagy in Parkinson's disease
    Shashank Masaldan, Sylvie Callegari, Grant Dewson
    Biochemical Society Transactions.2022; 50(2): 783.     CrossRef
  • Worldwide trends in mortality related to Parkinson's disease in the period of 1994–2019: Analysis of vital registration data from the WHO Mortality Database
    Ioannis C. Lampropoulos, Foteini Malli, Olga Sinani, Konstantinos I. Gourgoulianis, Georgia Xiromerisiou
    Frontiers in Neurology.2022;[Epub]     CrossRef
  • Effects of physician visit frequency for Parkinson’s disease treatment on mortality, hospitalization, and costs: a retrospective cohort study
    Takako Fujita, Akira Babazono, Sung-a Kim, Aziz Jamal, Yunfei Li
    BMC Geriatrics.2021;[Epub]     CrossRef
Brief communications
Knowledge, Attitude, and Perceptions about Deep Brain Stimulation for Parkinson’s Disease: Observations from a Single Indian Center
Shweta Prasad, Amitabh Bhattacharya, Lulup Kumar Sahoo, Dhruv Batra, Nitish Kamble, Ravi Yadav, Dwarakanath Srinivas, Pramod Kumar Pal
J Mov Disord. 2021;14(1):60-64.   Published online September 21, 2020
DOI: https://doi.org/10.14802/jmd.20066
  • 5,436 View
  • 135 Download
  • 5 Web of Science
  • 5 Crossref
AbstractAbstract PDFSupplementary Material
Objective
Willingness to undergo deep brain stimulation (DBS) among patients with Parkinson’s disease (PD) and their overall satisfaction with the procedure is highly dependent upon expectations, which are based on the core concepts of knowledge, attitude and perceptions. The present study aims to evaluate these factors in patients and caregivers with PD from a single tertiary care hospital in India.
Methods
A structured questionnaire designed to assess the knowledge, attitude and perceptions about DBS in PD was administered to 400 patients with PD and their caregivers.
Results
A very small proportion of patients and caregivers were aware of DBS. Even those who claimed to be aware of DBS were inadequately informed and had incorrect knowledge, which led to wrong attitudes and perceptions.
Conclusion
There are very significant knowledge gaps and misconceptions regarding DBS among patients with PD and caregivers. Adequate and appropriate education is necessary to clarify these misconceptions to avoid the development of unrealistic expectations and poor satisfaction.

Citations

Citations to this article as recorded by  
  • Know DBS: patient perceptions and knowledge of deep brain stimulation in Parkinson’s disease
    Meagen Salinas, Umar Yazdani, Austin Oblack, Bradley McDaniels, Nida Ahmed, Bilal Haque, Nader Pouratian, Shilpa Chitnis
    Therapeutic Advances in Neurological Disorders.2024;[Epub]     CrossRef
  • Assessment of Knowledge and Perception Regarding Deep Brain Stimulation Among Medical Students in Saudi Arabia
    Sarah S Aldharman, Fadi A Munhish, Haila A Alabssi, Maryam A Alamer, Fay A Althunayyan, Majidah H Halawi, Shireen H Elfaham, Taghreed A Alsinani, Saud A Alnaaim
    Cureus.2023;[Epub]     CrossRef
  • Deep Brain Stimulation for Parkinson's Disease‐the Developing World's Perspective
    Khushboo Patel, Divya Kalikavil Puthanveedu, Asish Vijayaraghavan, Krishnakumar Kesavapisharady, Gangadhara Sarma, Sankara P. Sarma, Syam Krishnan
    Movement Disorders Clinical Practice.2023; 10(12): 1750.     CrossRef
  • How Parkinson’s patients in the USA perceive deep brain stimulation in the 21st century: Results of a nationwide survey
    Daniel Alfonso, Laura Y. Cabrera, Christos Sidiropoulos, Fei Wang, Harini Sarva
    Journal of Clinical Neuroscience.2022; 95: 20.     CrossRef
  • Caregiver Burden in Partners of Parkinsonian Patients with Deep Brain Stimulation
    Eileen Gülke, Monika Pötter-Nerger
    Brain Sciences.2022; 12(2): 238.     CrossRef
Deep Brain Stimulation Battery Exhaustion during the COVID-19 Pandemic: Crisis within a Crisis
Vikram Venkappayya Holla, Koti Neeraja, Bharath Kumar Surisetti, Shweta Prasad, Nitish Kamble, Dwarakanath Srinivas, Ravi Yadav, Pramod Kumar Pal
J Mov Disord. 2020;13(3):218-222.   Published online August 31, 2020
DOI: https://doi.org/10.14802/jmd.20073
  • 8,036 View
  • 115 Download
  • 16 Web of Science
  • 5 Crossref
AbstractAbstract PDF
Objective
The novel coronavirus disease (COVID-19) pandemic and public health measures to control it have resulted in unique challenges in the management of patients with deep brain stimulation (DBS). We report our experience with the management of acute worsening of symptoms due to battery exhaustion in 3 patients with DBS.
Methods
Patients with DBS for movement disorders who visited the emergency room due to battery exhaustion during the nationwide lockdown from April to May 2020 were included.
Results
Two patients with subthalamic nucleus-DBS for Parkinson’s disease (PD) and one with globus pallidus interna-DBS for generalized dystonia presented with acute worsening of symptoms due to battery exhaustion. Urgent battery replacement was performed in both patients with PD. The patient with generalized dystonia was managed with medication adjustment as he chose to defer battery replacement.
Conclusion
DBS battery replacement can be an emergency. Decisions regarding DBS battery replacement should be individualized during this COVID-19 pandemic.

Citations

Citations to this article as recorded by  
  • Effects of COVID-19 on Synaptic and Neuronal Degeneration
    Mohammed S. Alqahtani, Mohamed Abbas, Mohammad Y. Alshahrani, Khulud Alabdullh, Amjad Alqarni, Fawaz F. Alqahtani, Layal K. Jambi, Adnan Alkhayat
    Brain Sciences.2023; 13(1): 131.     CrossRef
  • Needs and Perceptions of Patients With Dystonia During the COVID-19 Pandemic: A Qualitative Framework Analysis of Survey Responses From Italy
    Vittorio Rispoli, Matías Eduardo Díaz Crescitelli, Francesco Cavallieri, Francesca Antonelli, Stefano Meletti, Luca Ghirotto, Franco Valzania
    Frontiers in Neurology.2022;[Epub]     CrossRef
  • Parkinsonism hyperpyraexia syndrome in Parkinson's disease patients undergoing deep brain stimulation: An indirect consequence of COVID-19 lockdowns
    Onanong Phokaewvarangkul, Sasivimol Virameteekul, Roongroj Bhidayasiri
    Parkinsonism & Related Disorders.2021; 87: 39.     CrossRef
  • An Investigation Into Miniaturised Closed-Loop DBS Devices
    Dean M. Corva, Scott D. Adams, Kevin E. Bennet, Parastoo Hashemi, Michael Berk, Abbas Z. Kouzani
    IEEE Transactions on Medical Robotics and Bionics.2021; 3(3): 671.     CrossRef
  • Effects of COVID-19 Lockdown on Movement Disorders Patients With Deep Brain Stimulation: A Multicenter Survey
    Carla Piano, Francesco Bove, Tommaso Tufo, Isabella Imbimbo, Danilo Genovese, Alessandro Stefani, Massimo Marano, Antonella Peppe, Livia Brusa, Rocco Cerroni, Francesco Motolese, Enrico Di Stasio, Marianna Mazza, Antonio Daniele, Alessandro Olivi, Paolo C
    Frontiers in Neurology.2020;[Epub]     CrossRef
Review Article
Update on Current Technologies for Deep Brain Stimulation in Parkinson’s Disease
Michelle Paff, Aaron Loh, Can Sarica, Andres M. Lozano, Alfonso Fasano
J Mov Disord. 2020;13(3):185-198.   Published online August 31, 2020
DOI: https://doi.org/10.14802/jmd.20052
  • 18,627 View
  • 740 Download
  • 51 Web of Science
  • 52 Crossref
AbstractAbstract PDF
Deep brain stimulation (DBS) is becoming increasingly central in the treatment of patients with Parkinson’s disease and other movement disorders. Recent developments in DBS lead and implantable pulse generator design provide increased flexibility for programming, potentially improving the therapeutic benefit of stimulation. Directional DBS leads may increase the therapeutic window of stimulation by providing a means of avoiding current spread to structures that might give rise to stimulation-related side effects. Similarly, control of current to individual contacts on a DBS lead allows for shaping of the electric field produced between multiple active contacts. The following review aims to describe the recent developments in DBS system technology and the features of each commercially available DBS system. The advantages of each system are reviewed, and general considerations for choosing the most appropriate system are discussed.

Citations

Citations to this article as recorded by  
  • Current DBS programming
    Yıldız Değirmenci
    Deep Brain Stimulation.2024; 4: 29.     CrossRef
  • Technological developments in electric-based DBS
    Mehmet Tonge
    Deep Brain Stimulation.2024; 4: 36.     CrossRef
  • Movement disorder Deep brain stimulation Hybridization: Patient and caregiver outcomes
    Nathan Esplin, Dorian Kusyk, Seung W Jeong, Shahed Elhamdani, Khaled Abdel Aziz, Amanda Webb, Cindy Angle, Donald Whiting, Nestor D. Tomycz
    Clinical Parkinsonism & Related Disorders.2024; 10: 100234.     CrossRef
  • Deep brain stimulation of the subthalamic nucleus in Parkinson disease 2013–2023: where are we a further 10 years on?
    Andrew Brian O’Keeffe, Anca Merla, Keyoumars Ashkan
    British Journal of Neurosurgery.2024; : 1.     CrossRef
  • Preventing Sudden Cessation of Implantable Pulse Generators in Deep Brain Stimulation: A Systematic Review and Protocol Proposal
    Spencer J. Oslin, Helen H. Shi, Andrew K. Conner
    Stereotactic and Functional Neurosurgery.2024; 102(2): 127.     CrossRef
  • Janus microparticles-based targeted and spatially-controlled piezoelectric neural stimulation via low-intensity focused ultrasound
    Mertcan Han, Erdost Yildiz, Ugur Bozuyuk, Asli Aydin, Yan Yu, Aarushi Bhargava, Selcan Karaz, Metin Sitti
    Nature Communications.2024;[Epub]     CrossRef
  • Spinal Cord Stimulation for Parkinson’s Disease: A Systematic Review and Meta-Analysis of Pain and Motor Outcomes
    Can Sarica, Ajmal Zemmar, Omid Yousefi, Andrew C. Yang, Ayse Uzuner, Zhiyuan Sheng, Brendan Santyr, Nardin Samuel, Michael Colditz, Artur Vetkas, Jürgen Germann, Cletus Cheyuo, Mohammadmahdi Sabahi, Raja Niranjan Jani, Ghazaleh Darmani, Kazuaki Yamamoto,
    Stereotactic and Functional Neurosurgery.2023; 101(4): 244.     CrossRef
  • Long-term motor outcomes of deep brain stimulation of the globus pallidus interna in Parkinson's disease patients: Five-year follow-up
    Yun Su Hwang, Sungyang Jo, Seung Hyun Lee, Nayoung Kim, Mi-Sun Kim, Sang Ryong Jeon, Sun Ju Chung
    Journal of the Neurological Sciences.2023; 444: 120484.     CrossRef
  • Implementing automation in deep brain stimulation: has the time come?
    Marco Bonizzato, Alfonso Fasano
    The Lancet Digital Health.2023; 5(2): e52.     CrossRef
  • Proceedings of the 10th annual deep brain stimulation think tank: Advances in cutting edge technologies, artificial intelligence, neuromodulation, neuroethics, interventional psychiatry, and women in neuromodulation
    Joshua K. Wong, Helen S. Mayberg, Doris D. Wang, R. Mark Richardson, Casey H. Halpern, Lothar Krinke, Mattia Arlotti, Lorenzo Rossi, Alberto Priori, Sara Marceglia, Ro’ee Gilron, James F. Cavanagh, Jack W. Judy, Svjetlana Miocinovic, Annaelle D. Devergnas
    Frontiers in Human Neuroscience.2023;[Epub]     CrossRef
  • Deep brain stimulation: new programming algorithms and teleprogramming
    Renato Puppi Munhoz, Ghadh Albuainain
    Expert Review of Neurotherapeutics.2023; 23(5): 467.     CrossRef
  • Impact of modeled field of view in electroconvulsive therapy current flow simulations
    Alexander Guillen, Christopher C. Abbott, Zhi-De Deng, Yu Huang, Paula Pascoal-Faria, Dennis Q. Truong, Abhishek Datta
    Frontiers in Psychiatry.2023;[Epub]     CrossRef
  • Access to device-aided therapies in advanced Parkinson’s disease: navigating clinician biases, patient preference, and prognostic uncertainty
    Manon Auffret, Daniel Weiss, Fabrizio Stocchi, Marc Vérin, Wolfgang H. Jost
    Journal of Neural Transmission.2023; 130(11): 1411.     CrossRef
  • Multifunctional Fiber‐Based Optoacoustic Emitter as a Bidirectional Brain Interface
    Nan Zheng, Ying Jiang, Shan Jiang, Jongwoon Kim, Guo Chen, Yueming Li, Ji‐Xin Cheng, Xiaoting Jia, Chen Yang
    Advanced Healthcare Materials.2023;[Epub]     CrossRef
  • Neurological Insights into Sleep Disorders in Parkinson’s Disease
    Subramanian Thangaleela, Bhagavathi Sundaram Sivamaruthi, Periyanaina Kesika, Subramanian Mariappan, Subramanian Rashmi, Thiwanya Choeisoongnern, Phakkharawat Sittiprapaporn, Chaiyavat Chaiyasut
    Brain Sciences.2023; 13(8): 1202.     CrossRef
  • Investigation of a Deep Brain Stimulator (DBS) System
    Jennifer Whitestone, Anmar Salih, Tarun Goswami
    Bioengineering.2023; 10(10): 1160.     CrossRef
  • Thirty Years of Global Deep Brain Stimulation: “Plus ça change, plus c’est la même chose”?
    Marwan Hariz, Laura Cif, Patric Blomstedt
    Stereotactic and Functional Neurosurgery.2023; 101(6): 395.     CrossRef
  • The Safety to Switch from Constant Voltage to Constant Current with a Mixed Internal Pulse Generator in Deep Brain Stimulation
    Gülşah Öztürk, Kemal Paksoy
    Annals of Indian Academy of Neurology.2023; 26(4): 507.     CrossRef
  • Advances in Deep Brain Stimulation: From Mechanisms to Applications
    Stephanie S. Sandoval-Pistorius, Mallory L. Hacker, Allison C. Waters, Jing Wang, Nicole R. Provenza, Coralie de Hemptinne, Kara A. Johnson, Melanie A. Morrison, Stephanie Cernera
    The Journal of Neuroscience.2023; 43(45): 7575.     CrossRef
  • Brain stimulation treatments in epilepsy: Basic mechanisms and clinical advances
    Thomas J. Foutz, Michael Wong
    Biomedical Journal.2022; 45(1): 27.     CrossRef
  • Neurodegenerative disorders management: state-of-art and prospects of nano-biotechnology
    Raj Kumar, Keshaw Ram Aadil, Kunal Mondal, Yogendra Kumar Mishra, David Oupicky, Seeram Ramakrishna, Ajeet Kaushik
    Critical Reviews in Biotechnology.2022; 42(8): 1180.     CrossRef
  • Sleep and circadian rhythms in Parkinson’s disease and preclinical models
    Jeremy Hunt, Elizabeth J. Coulson, Rajendram Rajnarayanan, Henrik Oster, Aleksandar Videnovic, Oliver Rawashdeh
    Molecular Neurodegeneration.2022;[Epub]     CrossRef
  • Jose Delgado: A controversial trailblazer in neuromodulation
    Nicholas D. Lorusso, Uma R. Mohan, Joshua Jacobs
    Artificial Organs.2022; 46(4): 531.     CrossRef
  • Local and distant cortical responses to single pulse intracranial stimulation in the human brain are differentially modulated by specific stimulation parameters
    Angelique C. Paulk, Rina Zelmann, Britni Crocker, Alik S. Widge, Darin D. Dougherty, Emad N. Eskandar, Daniel S. Weisholtz, R. Mark Richardson, G. Rees Cosgrove, Ziv M. Williams, Sydney S. Cash
    Brain Stimulation.2022;[Epub]     CrossRef
  • Proceedings of the Ninth Annual Deep Brain Stimulation Think Tank: Advances in Cutting Edge Technologies, Artificial Intelligence, Neuromodulation, Neuroethics, Pain, Interventional Psychiatry, Epilepsy, and Traumatic Brain Injury
    Joshua K. Wong, Günther Deuschl, Robin Wolke, Hagai Bergman, Muthuraman Muthuraman, Sergiu Groppa, Sameer A. Sheth, Helen M. Bronte-Stewart, Kevin B. Wilkins, Matthew N. Petrucci, Emilia Lambert, Yasmine Kehnemouyi, Philip A. Starr, Simon Little, Juan Ans
    Frontiers in Human Neuroscience.2022;[Epub]     CrossRef
  • Past, Present, and Future of Deep Brain Stimulation: Hardware, Software, Imaging, Physiology and Novel Approaches
    Jessica Frey, Jackson Cagle, Kara A. Johnson, Joshua K. Wong, Justin D. Hilliard, Christopher R. Butson, Michael S. Okun, Coralie de Hemptinne
    Frontiers in Neurology.2022;[Epub]     CrossRef
  • Parkinson’s Disease Management via Wearable Sensors: A Systematic Review
    Huma Mughal, Abdul Rehman Javed, Muhammad Rizwan, Ahmad S. Almadhor, Natalia Kryvinska
    IEEE Access.2022; 10: 35219.     CrossRef
  • Conversion to Hybrid Deep Brain Stimulation System to Enable Multi‐Contact Fractionation Can be Therapeutic
    Disep I. Ojukwu, Allan R. Wang, Traci S. Hornbeck, Erika A. Lim, Jennifer Sharrard, Rohit Dhall, Vivek P. Buch, Casey H. Halpern
    Movement Disorders.2022; 37(6): 1321.     CrossRef
  • Developments in Deep Brain Stimulators for Successful Aging Towards Smart Devices—An Overview
    Angelito A. Silverio, Lean Angelo A. Silverio
    Frontiers in Aging.2022;[Epub]     CrossRef
  • Single-interface bioelectronic medicines—concept, clinical applications and preclinical data
    Cristian Sevcencu
    Journal of Neural Engineering.2022; 19(3): 031001.     CrossRef
  • Current Steering Using Multiple Independent Current Control Deep Brain Stimulation Technology Results in Distinct Neurophysiological Responses in Parkinson’s Disease Patients
    Jana Peeters, Alexandra Boogers, Tine Van Bogaert, Robin Gransier, Jan Wouters, Bart Nuttin, Myles Mc Laughlin
    Frontiers in Human Neuroscience.2022;[Epub]     CrossRef
  • Managing Intractable Symptoms of Parkinson's Disease: A Nonsurgical Approach Employing Infralow Frequency Neuromodulation
    Stella B. Legarda, P. Andreas Michas-Martin, Dana McDermott
    Frontiers in Human Neuroscience.2022;[Epub]     CrossRef
  • Directional Deep Brain Stimulation in the Treatment of Parkinson's Disease
    Akash Mishra, Ritesh A Ramdhani
    Neurology.2022; 18(1): 64.     CrossRef
  • Approach to the Treatment of Pediatric Dystonia
    Carolina Gorodetsky, Alfonso Fasano
    Dystonia.2022;[Epub]     CrossRef
  • CRISPR and iPSCs: Recent Developments and Future Perspectives in Neurodegenerative Disease Modelling, Research, and Therapeutics
    Tirthankar Sen, Rajkumar P. Thummer
    Neurotoxicity Research.2022; 40(5): 1597.     CrossRef
  • Encoding type, medication, and deep brain stimulation differentially affect memory-guided sequential reaching movements in Parkinson's disease
    Fabian J. David, Yessenia M. Rivera, Tara K. Entezar, Rishabh Arora, Quentin H. Drane, Miranda J. Munoz, Joshua M. Rosenow, Sepehr B. Sani, Gian D. Pal, Leonard Verhagen-Metman, Daniel M. Corcos
    Frontiers in Neurology.2022;[Epub]     CrossRef
  • Remote programming for subthalamic deep brain stimulation in Parkinson's disease
    Si Chen, Shu-jun Xu, Wei-guo Li, Teng Chen, Chao Li, Shuo Xu, Ning Yang, Yi-ming Liu
    Frontiers in Neurology.2022;[Epub]     CrossRef
  • Longevity of Deep Brain Stimulation Batteries; a Global Survey of Neurosurgeons and Neurologists
    Marwan Hariz, Gun‐Marie Hariz, Patric Blomstedt
    Movement Disorders.2021; 36(5): 1273.     CrossRef
  • Basic Tips: How Do I Start Programming Deep Brain Stimulation in Parkinson Disease Patients?
    Carolina Gorodetsky, Alfonso Fasano
    Movement Disorders Clinical Practice.2021; 8(4): 639.     CrossRef
  • Deep brain stimulation: Challenges at the tissue‐electrode interface and current solutions
    Emily Kolaya, Bonnie L. Firestein
    Biotechnology Progress.2021;[Epub]     CrossRef
  • An Update on Medical and Surgical Treatments of Parkinson’s Disease
    Dipali Nemade, Thyagarajan Subramanian, Vikram Shivkumar
    Aging and disease.2021; 12(4): 1021.     CrossRef
  • Experimental Characterization of Ferroelectric Capacitor Circuits for the Realization of Simply Designed Electroceuticals
    Yves Olsommer, Frank R. Ihmig
    Electronic Materials.2021; 2(3): 299.     CrossRef
  • Flexible vs. standard subthalamic stimulation in Parkinson disease: A double-blind proof-of-concept cross-over trial
    Derrick Soh, Ricardo Maciel, Musleh Algarni, Karlo Lizarraga, Aaron Loh, Jürgen Germann, Gavin Elias, Alexandre Boutet, Renato P. Munhoz, Suneil K. Kalia, Mojgan Hodaie, Andres M. Lozano, Alfonso Fasano
    Parkinsonism & Related Disorders.2021; 89: 93.     CrossRef
  • Telemedicine and Deep brain stimulation - Current practices and recommendations
    Vibhash D. Sharma, Delaram Safarpour, Shyamal H. Mehta, Nora Vanegas-Arroyave, Daniel Weiss, Jeffrey W. Cooney, Zoltan Mari, Alfonso Fasano
    Parkinsonism & Related Disorders.2021; 89: 199.     CrossRef
  • Subspace-based predictive control of Parkinson’s disease: A model-based study
    Mahboubeh Ahmadipour, Mojtaba Barkhordari-Yazdi, Saeid R. Seydnejad
    Neural Networks.2021; 142: 680.     CrossRef
  • Advances in Triboelectric Nanogenerators for Self‐Powered Regenerative Medicine
    Samira Parandeh, Niloofar Etemadi, Mahshid Kharaziha, Guorui Chen, Ardo Nashalian, Xiao Xiao, Jun Chen
    Advanced Functional Materials.2021;[Epub]     CrossRef
  • Implantable Pulse Generators for Deep Brain Stimulation: Challenges, Complications, and Strategies for Practicality and Longevity
    Can Sarica, Christian Iorio-Morin, David H. Aguirre-Padilla, Ahmed Najjar, Michelle Paff, Anton Fomenko, Kazuaki Yamamoto, Ajmal Zemmar, Nir Lipsman, George M. Ibrahim, Clement Hamani, Mojgan Hodaie, Andres M. Lozano, Renato P. Munhoz, Alfonso Fasano, Sun
    Frontiers in Human Neuroscience.2021;[Epub]     CrossRef
  • Microstimulation Is a Promising Approach in Achieving Better Lead Placement in Subthalamic Nucleus Deep Brain Stimulation Surgery
    Lin Shi, Shiying Fan, Tianshuo Yuan, Huaying Fang, Jie Zheng, Zunyu Xiao, Yu Diao, Guanyu Zhu, Quan Zhang, Huanguang Liu, Hua Zhang, Fangang Meng, Jianguo Zhang, Anchao Yang
    Frontiers in Neurology.2021;[Epub]     CrossRef
  • Revisiting brain stimulation in Parkinson’s disease
    Carola A. Haas
    Science.2021; 374(6564): 153.     CrossRef
  • A New Implantable Closed-Loop Clinical Neural Interface: First Application in Parkinson’s Disease
    Mattia Arlotti, Matteo Colombo, Andrea Bonfanti, Tomasz Mandat, Michele Maria Lanotte, Elena Pirola, Linda Borellini, Paolo Rampini, Roberto Eleopra, Sara Rinaldo, Luigi Romito, Marcus L. F. Janssen, Alberto Priori, Sara Marceglia
    Frontiers in Neuroscience.2021;[Epub]     CrossRef
  • Update on Parkinson's Disease Therapy
    Rebecca M Gilbert
    Neurology.2021; 17(2): 92.     CrossRef
  • Deep Brain Stimulation for Parkinson's Disease: Currents Status and Emerging Concepts
    PareshK Doshi, Deepak Das
    Neurology India.2020; 68(8): 179.     CrossRef
Original Article
Long-term Effects of Bilateral Subthalamic Deep Brain Stimulation on Postural Instability and Gait Difficulty in Patients with Parkinson’s Disease
Hae-Won Shin, Mi Sun Kim, Sung Reul Kim, Sang Ryong Jeon, Sun Ju Chung
J Mov Disord. 2020;13(2):127-132.   Published online May 29, 2020
DOI: https://doi.org/10.14802/jmd.19081
  • 5,966 View
  • 209 Download
  • 7 Web of Science
  • 8 Crossref
AbstractAbstract PDF
Objective
The long-term effects of bilateral subthalamic nucleus deep brain stimulation (STN-DBS) on postural instability and gait difficulty (PIGD) in patients with Parkinson’s disease (PD) remain unclear. In this study, we aimed to evaluate the longterm effects of STN-DBS surgery on PIGD symptoms in patients with advanced-stage PD. Methods This study included 49 consecutively included patients with PD who underwent bilateral STN-DBS. The Unified Parkinson’s Disease Rating Scale (UPDRS) scores and subscores for PIGD were assessed at baseline and at 1, 3, and 5 years postoperatively. The PIGD subscore was divided into PIGD-motor and PIGD-activities of daily living (ADL) scores according to parts III and II of the UPDRS, respectively. Results The PIGD-motor and PIGD-ADL scores at the “medication-off” state improved at 3 and 5 years, respectively. Overall, the UPDRS III and II scores at “medication-off” improved at 5 years. The UPDRS IV score also significantly improved and the levodopa equivalent daily dosage decreased at all follow-ups. Finally, the PIGD-motor score at baseline was able to predict long-term improvement in the PIGD-motor score at the 5-year follow-up. Conclusion The STN-DBS has both short- and long-term effects on PIGD, as well as overall motor function, in patients with advanced PD. The degree of PIGD at the preoperative evaluation can be used to predict long-term outcomes after STN-DBS surgery.

Citations

Citations to this article as recorded by  
  • Effects of subthalamic nucleus deep brain stimulation using different frequency programming paradigms on axial symptoms in advanced Parkinson’s disease
    Yifeng Cheng, Guangrui Zhao, Lei Chen, Deqiu Cui, Chunjuan Wang, Keke Feng, Shaoya Yin
    Acta Neurochirurgica.2024;[Epub]     CrossRef
  • Long-term motor outcomes of deep brain stimulation of the globus pallidus interna in Parkinson's disease patients: Five-year follow-up
    Yun Su Hwang, Sungyang Jo, Seung Hyun Lee, Nayoung Kim, Mi-Sun Kim, Sang Ryong Jeon, Sun Ju Chung
    Journal of the Neurological Sciences.2023; 444: 120484.     CrossRef
  • Smartwatch gait coordination index: New measure for human gait utilizing smartwatch sensor
    Sumin Han, Rob Paul
    Medicine.2023; 102(12): e33267.     CrossRef
  • WITHDRAWN: Laterality and frequency settings of subthalamic nucleus DBS for Parkinson's disease: A systematic review and network meta-analysis
    Rajiv Dharnipragada, Lalitha S. Denduluri, Anant Naik, Mario Bertogliat, Matthew Awad, Salman Ikramuddin, Michael C. Park
    Parkinsonism & Related Disorders.2023; : 105455.     CrossRef
  • Frequency settings of subthalamic nucleus DBS for Parkinson's disease: A systematic review and network meta-analysis
    Rajiv Dharnipragada, Lalitha S. Denduluri, Anant Naik, Mario Bertogliat, Matthew Awad, Salman Ikramuddin, Michael C. Park
    Parkinsonism & Related Disorders.2023; 116: 105809.     CrossRef
  • Unlocking potential: low frequency subthalamic nucleus stimulation enhances executive function in Parkinson’s disease patients with postural instability/gait disturbance
    Guofan Qin, Hutao Xie, Lin Shi, Baotian Zhao, Yifei Gan, Zixiao Yin, Yichen Xu, Xin Zhang, Yaojing Chen, Yin Jiang, Quan Zhang, Jianguo Zhang
    Frontiers in Neuroscience.2023;[Epub]     CrossRef
  • The Role of Microelectrode Recording in Deep Brain Stimulation Surgery for Parkinson’s Disease: A Systematic Review and Meta-Analysis
    R. Saman Vinke, Martin Geerlings, Ashok K. Selvaraj, Dejan Georgiev, Bastiaan R. Bloem, Rianne A.J. Esselink, Ronald H.M.A. Bartels
    Journal of Parkinson's Disease.2022; 12(7): 2059.     CrossRef
  • Axial impairment and falls in Parkinson’s disease: 15 years of subthalamic deep brain stimulation
    Alessandro Zampogna, Francesco Cavallieri, Francesco Bove, Antonio Suppa, Anna Castrioto, Sara Meoni, Pierre Pélissier, Emmanuelle Schmitt, Amélie Bichon, Eugénie Lhommée, Andrea Kistner, Stephan Chabardès, Eric Seigneuret, Valerie Fraix, Elena Moro
    npj Parkinson's Disease.2022;[Epub]     CrossRef
Case Report
Successful Pallidal Stimulation in a Patient with KMT2B-Related Dystonia
Jun Kyu Mun, Ah Reum Kim, Jong Hyeon Ahn, Minkyeong Kim, Jin Whan Cho, Jung-Il Lee, Kyung Rae Cho, Jinyoung Youn
J Mov Disord. 2020;13(2):154-158.   Published online April 6, 2020
DOI: https://doi.org/10.14802/jmd.19087
  • 6,891 View
  • 174 Download
  • 12 Web of Science
  • 13 Crossref
AbstractAbstract PDFSupplementary Material
Although the KMT2B gene was identified as a causative gene for early-onset generalized dystonia, the efficacy of deep brain stimulation (DBS) in KMT2B-related dystonia has not been clearly elucidated. Here, we describe a 28-year-old woman who developed generalized dystonia with developmental delay, microcephaly, short stature, and cognitive decline. She was diagnosed with KMT2B- related dystonia using whole-exome sequencing with a heterozygous frameshift insertion of c.515dupC (p.T172fs) in the KMT2B gene. Oral medications and botulinum toxin injection were not effective. The dystonia markedly improved with bilateral pallidal DBS (the Burke-Fahn-Marsden Dystonia Rating Scale score was reduced from 30 to 5 on the dystonia movement scale and from 11 to 1 on the disability scale), and she could walk independently. From this case, we suggest that bilateral globus pallidus internus DBS can be an effective treatment option for patients with KMT2B-related generalized dystonia.

Citations

Citations to this article as recorded by  
  • The role of genetics in the treatment of dystonia with deep brain stimulation: Systematic review and Meta-analysis
    Harini Sarva, Federico Rodriguez-Porcel, Francisco Rivera, Claudio Daniel Gonzalez, Samantha Barkan, Susmit Tripathi, Emilia Gatto, Pedro Garcia Ruiz
    Journal of the Neurological Sciences.2024; 459: 122970.     CrossRef
  • GPi DBS treatment outcome in children with monogenic dystonia: a case series and review of the literature
    Darko Chudy, Marina Raguž, Vladimira Vuletić, Valentino Rački, Eliša Papić, Nataša Nenadić Baranašić, Nina Barišić
    Frontiers in Neurology.2023;[Epub]     CrossRef
  • KMT2B-Related Dystonia in Indian Patients With Literature Review and Emphasis on Asian Cohort
    Debjyoti Dhar, Vikram V Holla, Riyanka Kumari, Neeharika Sriram, Jitender Saini, Ravi Yadav, Akhilesh Pandey, Nitish Kamble, Babylakshmi Muthusamy, Pramod Kumar Pal
    Journal of Movement Disorders.2023; 16(3): 285.     CrossRef
  • Transcriptional co-activators: emerging roles in signaling pathways and potential therapeutic targets for diseases
    Priyanka Dey Talukdar, Urmi Chatterji
    Signal Transduction and Targeted Therapy.2023;[Epub]     CrossRef
  • GPi‐DBS for KMT2B‐Associated Dystonia: Systematic Review and Meta‐Analysis
    Roopa Rajan, Kanwaljeet Garg, Arti Saini, Divya M. Radhakrishnan, Miryam Carecchio, Binukumar BK, Manmohan Singh, Achal K. Srivastava
    Movement Disorders Clinical Practice.2022; 9(1): 31.     CrossRef
  • Dystonic Tremor in Adult-onset DYT-KMT2B
    Rui Shimazaki, Jun Ikezawa, Ryoichi Okiyama, Kenko Azuma, Hiroyuki Akagawa, Kazushi Takahashi
    Internal Medicine.2022; 61(15): 2357.     CrossRef
  • Dystonia type 28 with early onset (DYT-KMT2B): a clinical case
    V. A. Bulanova, M. A. Bykanova, N. А. Kuleva
    Russian Journal of Child Neurology.2022; 17(3): 79.     CrossRef
  • Identification of a novel de novo KMT2B variant in a Greek dystonia patient via exome sequencing genotype–phenotype correlations of all published cases
    Chrysoula Marogianni, Despoina Georgouli, Katerina Dadouli, Panagiotis Ntellas, Dimitrios Rikos, Georgios M. Hadjigeorgiou, Cleanthi Spanaki, Georgia Xiromerisiou
    Molecular Biology Reports.2021; 48(1): 371.     CrossRef
  • Arching deep brain stimulation in dystonia types
    Han-Joon Kim, Beomseok Jeon
    Journal of Neural Transmission.2021; 128(4): 539.     CrossRef
  • Deep Brain Stimulation for Pediatric Dystonia
    Travis Larsh, Steve W. Wu, Sudhakar Vadivelu, Gerald A. Grant, Jennifer A. O'Malley
    Seminars in Pediatric Neurology.2021; 38: 100896.     CrossRef
  • Deep Brain Stimulation in KMT2B-Related Dystonia: Case Report and Review of the Literature With Special Emphasis on Dysarthria and Speech
    Maria Abel, Robert Pfister, Iman Hussein, Fahd Alsalloum, Christina Onyinzo, Simon Kappl, Michael Zech, Walter Demmel, Martin Staudt, Manfred Kudernatsch, Steffen Berweck
    Frontiers in Neurology.2021;[Epub]     CrossRef
  • Radiofrequency ablation for DYT‐28 dystonia: short term follow‐up of three adult cases
    Shiro Horisawa, Kenkou Azuma, Hiroyuki Akagawa, Taku Nonaka, Takakazu Kawamata, Takaomi Taira
    Annals of Clinical and Translational Neurology.2020; 7(10): 2047.     CrossRef
  • KMT2B-related disorders: expansion of the phenotypic spectrum and long-term efficacy of deep brain stimulation
    Laura Cif, Diane Demailly, Jean-Pierre Lin, Katy E Barwick, Mario Sa, Lucia Abela, Sony Malhotra, Wui K Chong, Dora Steel, Alba Sanchis-Juan, Adeline Ngoh, Natalie Trump, Esther Meyer, Xavier Vasques, Julia Rankin, Meredith W Allain, Carolyn D Applegate,
    Brain.2020; 143(11): 3242.     CrossRef
Brief communications
Rescue Levodopa/Carbidopa Intestinal Gel for Secondary Deep Brain Stimulation Failure
Juan Miguel Pilar Bautista, Genko Oyama, Maierdanjiang Nuermaimaiti, Satoko Sekimoto, Fuyuko Sasaki, Taku Hatano, Kenya Nishioka, Masanobu Ito, Atsushi Umemura, Yuji Ishibashi, Yasushi Shimo, Nobutaka Hattori
J Mov Disord. 2020;13(1):57-61.   Published online January 31, 2020
DOI: https://doi.org/10.14802/jmd.19051
  • 5,832 View
  • 154 Download
  • 6 Web of Science
  • 6 Crossref
AbstractAbstract PDF
Objective
The long-term efficacy of deep brain stimulation (DBS) for motor fluctuations in advanced Parkinson’s disease (PD) has been well established; however, motor fluctuations may recur over time despite multiple adjustments of DBS settings and medications.
Methods
We conducted a retrospective chart review of three patients for whom levodopa-carbidopa intestinal gel (LCIG) was additionally administered as a rescue therapy for secondary DBS failure due to the recurrence of motor fluctuations.
Results
The three patients had advanced PD with a disease duration of 14–19 years, and had undergone DBS for motor fluctuations refractory to standard medical management. LCIG was administered to the patients because of symptom recurrence years after DBS and provided complementary effects in all patients.
Conclusion
The cases presented here show that rescue LCIG therapy may be a complementary treatment option for patients with post-DBS advanced PD who have a recurrence of troublesome motor complications.

Citations

Citations to this article as recorded by  
  • Nationwide Retrospective Analysis of Combinations of Advanced Therapies in Patients With Parkinson Disease
    Dominik Pürner, Mohammad Hormozi, Daniel Weiß, Michael T. Barbe, Hannah Jergas, Tino Prell, Eileen Gülke, Monika Pötter-Nerger, Björn Falkenburger, Lisa Klingelhöfer, Pia K. Gutsmiedl, Bernhard Haslinger, Angela M. Jochim, Andreas Wolff, Nils Schröter, Mi
    Neurology.2023;[Epub]     CrossRef
  • Combining Device‐Aided Therapies in Parkinson's Disease: A Case Series and a Literature Review
    Iro Boura, Nikolaos Haliasos, Ιrene‐Areti Giannopoulou, Dimitrios Karabetsos, Cleanthe Spanaki
    Movement Disorders Clinical Practice.2021; 8(5): 750.     CrossRef
  • Combined and Sequential Treatment with Deep Brain Stimulation and Continuous Intrajejunal Levodopa Infusion for Parkinson’s Disease
    Daniël van Poppelen, Annelie N.M. Tromp, Rob M.A. de Bie, Joke M. Dijk
    Journal of Personalized Medicine.2021; 11(6): 547.     CrossRef
  • Personalised Advanced Therapies in Parkinson’s Disease: The Role of Non-Motor Symptoms Profile
    Valentina Leta, Haidar S. Dafsari, Anna Sauerbier, Vinod Metta, Nataliya Titova, Lars Timmermann, Keyoumars Ashkan, Michael Samuel, Eero Pekkonen, Per Odin, Angelo Antonini, Pablo Martinez-Martin, Miriam Parry, Daniel J. van Wamelen, K. Ray Chaudhuri
    Journal of Personalized Medicine.2021; 11(8): 773.     CrossRef
  • Parkinson’s Kinetigraph in the Selection of Levodopa-Carbidopa Intestinal Gel for Motor Fluctuations Refractory to Deep Brain Stimulation
    Yassine Noui, Monty Adam Silverdale, Julian Evans, Lucy Partington-Smith, Christopher Kobylecki
    Journal of Movement Disorders.2021; 14(3): 239.     CrossRef
  • The Choice Between Advanced Therapies for Parkinson’s Disease Patients: Why, What, and When?
    Joke M. Dijk, Alberto J. Espay, Regina Katzenschlager, Rob M.A. de Bie, Bastiaan R. Bloem, Patrik Brundin
    Journal of Parkinson's Disease.2020; 10(s1): S65.     CrossRef
The Effect of Globus Pallidus Interna Deep Brain Stimulation on a Dystonia Patient with the GNAL Mutation Compared to Patients with DYT1 and DYT6
Jong Hyeon Ahn, Ah Reum Kim, Nayoung K. D. Kim, Woong-Yang Park, Ji Sun Kim, Minkyeong Kim, Jongkyu Park, Jung-Il Lee, Jin Whan Cho, Kyung Rae Cho, Jinyoung Youn
J Mov Disord. 2019;12(2):120-124.   Published online May 30, 2019
DOI: https://doi.org/10.14802/jmd.19006
  • 5,888 View
  • 139 Download
  • 11 Web of Science
  • 12 Crossref
AbstractAbstract PDFSupplementary Material
Objective
The aim of this study was to investigate the efficacy of globus pallidus interna deep brain stimulation (GPi-DBS) for treating dystonia due to the GNAL mutation.
Methods
We provide the first report of a dystonia patient with a genetically confirmed GNAL mutation in the Korean population and reviewed the literature on patients with the GNAL mutation who underwent GPi-DBS. We compared the effectiveness of DBS in patients with the GNAL mutation compared to that in patients with DYT1 and DYT6 in a previous study.
Results
Patients with the GNAL mutation and those with DYT1 had higher early responder rates (GNAL, 5/5, 100%; DYT1, 7/7, 100%) than did patients with DYT6 (p = 0.047). The responder rates at late follow-up did not differ statistically among the three groups (p = 0.278). The decrease in the dystonia motor scale score in the GNAL group was 46.9% at early follow-up and 63.4% at late follow-up.
Conclusion
GPi-DBS would be an effective treatment option for dystonia patients with the GNAL mutation who are resistant to medication or botulinum toxin treatment.

Citations

Citations to this article as recorded by  
  • The role of genetics in the treatment of dystonia with deep brain stimulation: Systematic review and Meta-analysis
    Harini Sarva, Federico Rodriguez-Porcel, Francisco Rivera, Claudio Daniel Gonzalez, Samantha Barkan, Susmit Tripathi, Emilia Gatto, Pedro Garcia Ruiz
    Journal of the Neurological Sciences.2024; 459: 122970.     CrossRef
  • A novel GNAL pathogenic variant leading to generalized dystonia: Immediate and sustained response to globus pallidus internus deep brain stimulation
    Luigi Michele Romito, Fabio Paio, Nico Golfrè Andreasi, Celeste Panteghini, Sara Rinaldo, Ahmet Kaymak, Alberto Mazzoni, Fabiana Colucci, Vincenzo Levi, Giuseppe Messina, Barbara Garavaglia, Roberto Eleopra
    Parkinsonism & Related Disorders.2023; 115: 105833.     CrossRef
  • Applicability of clinical genetic testing for deep brain stimulation treatment in monogenic Parkinson’s disease and monogenic dystonia: a multidisciplinary team perspective
    Valentino Rački, Mario Hero, Eliša Papić, Gloria Rožmarić, Nada Starčević Čizmarević, Darko Chudy, Borut Peterlin, Vladimira Vuletić
    Frontiers in Neuroscience.2023;[Epub]     CrossRef
  • Isolated dystonia: clinical and genetic updates
    Aloysius Domingo, Rachita Yadav, Laurie J. Ozelius
    Journal of Neural Transmission.2021; 128(4): 405.     CrossRef
  • Abnormal cerebellar function and tremor in a mouse model for non‐manifesting partially penetrant dystonia type 6
    Meike E. van der Heijden, Dominic J. Kizek, Ross Perez, Elena K. Ruff, Michelle E. Ehrlich, Roy V. Sillitoe
    The Journal of Physiology.2021; 599(7): 2037.     CrossRef
  • Pallidal Deep Brain Stimulation for Monogenic Dystonia: The Effect of Gene on Outcome
    Stephen Tisch, Kishore Raj Kumar
    Frontiers in Neurology.2021;[Epub]     CrossRef
  • Arching deep brain stimulation in dystonia types
    Han-Joon Kim, Beomseok Jeon
    Journal of Neural Transmission.2021; 128(4): 539.     CrossRef
  • The Efficacy and Predictors of Using GPi-DBS to Treat Early-Onset Dystonia: An Individual Patient Analysis
    Wenxiu Chen, Houyou Fan, Guohui Lu, Fushun Wang
    Neural Plasticity.2021; 2021: 1.     CrossRef
  • Deep brain stimulation in dystonia: State of art and future directions
    A. Macerollo, V. Sajin, M. Bonello, D. Barghava, S. H Alusi, P. R Eldridge, J. Osman-Farah
    Journal of Neuroscience Methods.2020; 340: 108750.     CrossRef
  • Successful Pallidal Stimulation in a Patient with KMT2B-Related Dystonia
    Jun Kyu Mun, Ah Reum Kim, Jong Hyeon Ahn, Minkyeong Kim, Jin Whan Cho, Jung-Il Lee, Kyung Rae Cho, Jinyoung Youn
    Journal of Movement Disorders.2020; 13(2): 154.     CrossRef
  • Clinical characteristics of ataxia-telangiectasia presenting dystonia as a main manifestation
    Minkyeong Kim, Ah Reum Kim, Jongkyu Park, Ji Sun Kim, Jong Hyeon Ahn, Woong-Yang Park, Nayoung K.D. Kim, Chung Lee, Nam-Soon Kim, Jin Whan Cho, Jinyoung Youn
    Clinical Neurology and Neurosurgery.2020; 199: 106267.     CrossRef
  • Reply to: The Spectrum of Movement Disorders in 18p Deletion Syndrome
    David Crosiers, Bettina Blaumeiser, Gert Van Goethem
    Movement Disorders Clinical Practice.2019; 6(8): 731.     CrossRef
Original Article
Pilot Study for Considering Subthalamic Nucleus Anatomy during Stimulation Using Directional Leads
Takashi Asahi, Kiyonobu Ikeda, Jiro Yamamoto, Hiroyuki Tsubono, Shuji Sato
J Mov Disord. 2019;12(2):97-102.   Published online April 5, 2019
DOI: https://doi.org/10.14802/jmd.18054
  • 6,376 View
  • 204 Download
  • 9 Web of Science
  • 9 Crossref
AbstractAbstract PDF
Objective
Directional leads are used for deep brain stimulation (DBS). Two of the four contacts of the leads are divided into three parts, enabling controlled stimulation in a circumferential direction. The direction of adverse effects evoked by DBS in the subthalamic nucleus (STN) and stimulation strategies using directional leads were evaluated. Methods Directional leads were implanted into the bilateral STN of six parkinsonian patients (1 man, 5 women; mean age 66.2 years). The contact centers were located within the upper border of the STN, and the locations were identified electrically using microrecordings. Adverse effects were evaluated with electrical stimulation (30 μs, 130 Hz, limit 11 mA) using the directional part of each lead after surgery, and the final stimulation direction was investigated. Unified Parkinson’s disease rating scale (UPDRS) scores were evaluated before and after DBS. Results Fifty-six motor and four sensory symptoms were evoked by stimulation; no adverse effect was evoked in 14 contacts. Motor and sensory symptoms were evoked by stimulation in the anterolateral direction and medial to posterolateral direction, respectively. Stimulation in the posteromedial direction produced adverse effects less frequently. The most frequently used contacts were located above the STN (63%), followed by the upper part of the STN (32%). The mean UPDRS part III and dyskinesia scores decreased after DBS from 30.2 ± 11.7 to 7.2 ± 2.9 and 3.3 ± 2.4 to 0.5 ± 0.8, respectively. Conclusion The incidence of adverse effects was low for the posteromedial stimulation of the STN. Placing the directional part of the lead above the STN may facilitate the control of dyskinesia.

Citations

Citations to this article as recorded by  
  • Directional deep brain stimulation in the management of Parkinson’s disease: efficacy and constraints—an analytical appraisal
    Mayara Tszesnioski Maçaneiro, Ana Clara Azevedo, Bruna Maurício Poerner, Milena Dangui da Silva, Andrei Koerbel
    Neurosurgical Review.2024;[Epub]     CrossRef
  • Globus pallidus internus versus subthalamic nucleus deep brain stimulation for isolated dystonia: A 3‐year follow‐up
    Suzhen Lin, Yimei Shu, Chencheng Zhang, Lingbing Wang, Peng Huang, Yixin Pan, Jianqing Ding, Bomin Sun, Dianyou Li, Yiwen Wu
    European Journal of Neurology.2023; 30(9): 2629.     CrossRef
  • Three-dimensional gait analysis of the effect of directional steering on gait in patients with Parkinson's disease
    Satoko Sekimoto, Genko Oyama, Kotatsu Bito, Masaru Tsuchiya, Sho Kikuchi, Baku Takimoto, Toshiki Ichihashi, Juan Miguel P. Bautista, Maierdanjiang Nuermaimaiti, Fuyuko Sasaki, Ryota Nakamura, Hirokazu Iwamuro, Masanobu Ito, Atsushi Umemura, Nobutaka Hatto
    Parkinsonism & Related Disorders.2023; 114: 105770.     CrossRef
  • Surgical Strategy for Directional Deep Brain Stimulation
    Hiroshi MASUDA, Hiroshi SHIROZU, Yosuke ITO, Masafumi FUKUDA, Yukihiko FUJII
    Neurologia medico-chirurgica.2022; 62(1): 1.     CrossRef
  • Do directional deep brain stimulation leads rotate after implantation?
    Marie T. Krüger, Yashar Naseri, Fabian Cavalloni, Peter C. Reinacher, Georg Kägi, Johannes Weber, Deborah Brogle, Oliver Bozinov, Stefan Hägele-Link, Florian Brugger
    Acta Neurochirurgica.2021; 163(1): 197.     CrossRef
  • Stimulation-Induced Dyskinesia After Subthalamic Nucleus Deep Brain Stimulation in Patients With Meige Syndrome
    Ning Wang, Kailiang Wang, Qiao Wang, Shiying Fan, Zonghui Fu, Feng Zhang, Lin Wang, Fangang Meng
    Neuromodulation: Technology at the Neural Interface.2021; 24(2): 286.     CrossRef
  • Deep brain stimulation programming strategies: segmented leads, independent current sources, and future technology
    Bhavana Patel, Shannon Chiu, Joshua K. Wong, Addie Patterson, Wissam Deeb, Matthew Burns, Pamela Zeilman, Aparna Wagle-Shukla, Leonardo Almeida, Michael S. Okun, Adolfo Ramirez-Zamora
    Expert Review of Medical Devices.2021; 18(9): 875.     CrossRef
  • Deep-Brain Stimulation for Essential Tremor and Other Tremor Syndromes: A Narrative Review of Current Targets and Clinical Outcomes
    Christian Iorio-Morin, Anton Fomenko, Suneil K. Kalia
    Brain Sciences.2020; 10(12): 925.     CrossRef
  • Dyskinesia‐inducing lead contacts optimize outcome of subthalamic stimulation in Parkinson's disease
    Walid Bouthour, Matthieu Béreau, Astrid Kibleur, André Zacharia, Emilie Tomkova Chaoui, Vanessa Fleury, Damien Benis, Shahan Momjian, Julien Bally, Christian Lüscher, Paul Krack, Pierre R. Burkhard
    Movement Disorders.2019; 34(11): 1728.     CrossRef
Case Report
Treatment of Hemichoreoathetosis with Arrhythmic Proximal Tremor after Stroke: The Role of Zona Incerta as a Target for Deep Brain Stimulation
Andrei Koerbel, Augusto Radünz do Amaral, Helena Bedatti Zeh, Eduardo Wollmann, Renata Fabiola Heil Koerbel, Carla Moro, Alexandre Luiz Longo
J Mov Disord. 2019;12(1):47-51.   Published online January 30, 2019
DOI: https://doi.org/10.14802/jmd.18032
  • 6,940 View
  • 111 Download
  • 3 Web of Science
  • 3 Crossref
AbstractAbstract PDFSupplementary Material
Deep brain stimulation (DBS) of the zona incerta has shown promising results in the reduction of medically refractory movement disorders. However, evidence supporting its efficacy in movement disorders secondary to hemorrhagic stroke or hemichoreoathetosis is limited. We describe a 48-year-old man who developed progressive hemichoreoathetosis with an arrhythmic, proximal tremor in his right arm following a thalamic hemorrhagic stroke. Pharmacological treatment was carried out with no change in the Abnormal Involuntary Movement Scale (AIMS) score after 4 weeks (14). After six sessions of botulinum toxin treatment, a subtle improvement in the AIMS score (13) was registered, but no clinical improvement was noted. The arrhythmic proximal movements were significantly improved after DBS of the zona incerta with a major decrease in the patient’s AIMS score (8). The response to DBS occurring after the failure of pharmacological and botulinum toxin treatments suggests that zona incerta DBS may be an alternative for postthalamic hemorrhage movement disorders.

Citations

Citations to this article as recorded by  
  • Deep brain stimulation for movement disorders after stroke: a systematic review of the literature
    Mitch R. Paro, Michal Dyrda, Srinath Ramanan, Grant Wadman, Stacey-Ann Burke, Isabella Cipollone, Cory Bosworth, Sarah Zurek, Patrick B. Senatus
    Journal of Neurosurgery.2022; : 1.     CrossRef
  • Deep brain stimulation for post-thalamic stroke complex movement disorders
    A. Macerollo, B. Hammersley, M. Bonello, J. Somerset, D. Bhargava, K. Das, J. Osman-Farah, P. R. Eldridge, S. H. Alusi
    Neurological Sciences.2021; 42(1): 337.     CrossRef
  • Neurologic Manifestations of Systemic Disease: Movement Disorders
    Giulietta M. Riboldi, Steven J. Frucht
    Current Treatment Options in Neurology.2021;[Epub]     CrossRef

JMD : Journal of Movement Disorders